Prospective observational study to evaluate appropriate dosage and efficacy of cephamycin and oxacephem for invasive UTI due to ESBL-E. coli
Not Applicable
- Conditions
- invasive UTI
- Registration Number
- JPRN-UMIN000041639
- Lead Sponsor
- CGM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 78
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with a history of invasive urinary tract infection within 4 weeks prior to onset - Patients with concomitant use of antimicrobial agents (beta-lactams, aminoglycosides, fluoroquinolones, ST-fusions, colistin, tigecycline, minomycin, doxycycline, nitrofurantoin, and fosfomycin) that may be effective against ESBL-producing E. coli in addition to the study drug. - Persons with a history of hypersensitivity to cephem and carbapenem antibiotics - Dialysis patients (hemodialysis and peritoneal dialysis) - Other items that the principal investigator deems inappropriate for inclusion in the research
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bacteriological and clinical efficacy in the early stage of treatment with intravenous cephamycin/oxacephem or carbapenem (days 4 to 6 after initiation of treatment [start date = day 1])
- Secondary Outcome Measures
Name Time Method